Research progress on risk factors of primary graft dysfunction after lung transplantation
-
摘要: 肺移植是治疗终末期肺疾病的唯一有效方式，但肺移植受者的早期预后远不如其他实体器官移植受者，其中原发性移植物功能障碍（PGD）是影响其预后的主要原因之一。PGD是肺移植术后早期发生的一种急性肺损伤，是导致肺移植受者术后早期死亡的主要原因。肺移植受者术后PGD发生的危险因素包括供者、受者、手术等多方面。本文对肺移植术后发生PGD的危险因素进行综述，旨在为临床提供参考。Abstract: Lung transplantation is the only effective approach to treat end-stage lung diseases. Nevertheless, early prognosis of lung transplant recipients is significantly worse than that of other solid organ transplant recipients. Primary graft dysfunction (PGD) is one of the main causes affecting clinical prognosis of the recipients. PGD is an early acute lung injury after lung transplantation, which is the main cause of early death of lung transplant recipients. Risk factors of PGD after lung transplantation consist of donor, recipient and operation, etc. In this article, the risk factors of PGD after lung transplantation were reviewed, aiming to provide reference for clinical practice.
-
[1] KHUSH KK, CHERIKH WS, CHAMBERS DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1056-1066. DOI: 10.1016/j.healun.2019.08.004. [2] CHRISTIE JD, VAN RAEMDONCK D, DE PERROT M, et al. Report of the ISHLT working group on primary lung graft dysfunction part I: introduction and methods[J]. J Heart Lung Transplant, 2005, 24(10): 1451-1453. DOI: 10.1016/j.healun.2005.03.004. [3] PORTEOUS MK, LEE JC. Primary graft dysfunction after lung transplantation[J]. Clin Chest Med, 2017, 38(4): 641-654. DOI: 10.1016/j.ccm.2017.07.005. [4] DIAMOND JM, ARCASOY S, KENNEDY CC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on primary lung graft dysfunction, part Ⅱ: epidemiology, risk factors, and outcomes-a 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant, 2017, 36(10): 1104-1113. DOI: 10.1016/j.healun.2017.07.020. [5] JIN Z, SUEN KC, WANG Z, et al. Review 2: primary graft dysfunction after lung transplant-pathophysiology, clinical considerations and therapeutic targets[J]. J Anesth, 2020, 34(5): 729-740. DOI: 10.1007/s00540-020-02823-6. [6] BHARAT A, KREISEL D. Immunopathogenesis of primary graft dysfunction after lung transplantation[J]. Ann Thorac Surg, 2018, 105(3): 671-674. DOI: 10.1016/j.athoracsur.2017.11.007. [7] LIU Y, LIU Y, SU L, et al. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and Meta-analysis[J]. PLoS One, 2014, 9(3): e92773. DOI: 10.1371/journal.pone.0092773. [8] KUNTZ CL, HADJILIADIS D, AHYA VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study[J]. Clin Transplant, 2009, 23(6): 819-830. DOI: 10.1111/j.1399-0012.2008.00951.x. [9] PORTEOUS MK, LEE JC, LEDERER DJ, et al. Clinical risk factors and prognostic model for primary graft dysfunction after lung transplantation in patients with pulmonary hypertension[J]. Ann Am Thorac Soc, 2017, 14(10): 1514-1522. DOI: 10.1513/AnnalsATS.201610-810OC. [10] LOWERY EM, KUHLMANN EA, MAHONEY EL, et al. Heavy alcohol use in lung donors increases the risk for primary graft dysfunction[J]. Alcohol Clin Exp Res, 2014, 38(11): 2853-2861. DOI: 10.1111/acer.12553. [11] PELAEZ A, MITCHELL PO, SHAH NS, et al. The role of donor chronic alcohol abuse in the development of primary graft dysfunction in lung transplant recipients[J]. Am J Med Sci, 2015, 349(2): 117-123. DOI: 10.1097/MAJ.0000000000000361. [12] CAMARGO MORENO M, LEWIS JB, KOVACS EJ, et al. Lung allograft donors with excessive alcohol use have increased levels of human antimicrobial peptide LL-37[J]. Alcohol, 2019, 80: 109-117. DOI: 10.1016/j.alcohol.2018.11.003. [13] WILKEY BJ, ABRAMS BA. Mitigation of primary graft dysfunction in lung transplantation: current understanding and hopes for the future[J]. Semin Cardiothorac Vasc Anesth, 2020, 24(1): 54-66. DOI: 10.1177/1089253219881980. [14] EBERLEIN M, REED RM, BOLUKBAS S, et al. Lung size mismatch and primary graft dysfunction after bilateral lung transplantation[J]. J Heart Lung Transplant, 2015, 34(2): 233-240. DOI: 10.1016/j.healun.2014.09.030. [15] PALLESCHI A, ROSSO L, MUSSO V, et al. Lung transplantation from donation after controlled cardiocirculatory death. systematic review and Meta-analysis[J]. Transplant Rev (Orlando), 2020, 34(1): 100513. DOI: 10.1016/j.trre.2019.100513. [16] VILLAVICENCIO MA, AXTELL AL, SPENCER PJ, et al. Lung transplantation from donation after circulatory death: United States and single-center experience[J]. Ann Thorac Surg, 2018, 106(6): 1619-1627. DOI: 10.1016/j.athoracsur.2018.07.024. [17] COSTA J, SHAH L, ROBBINS H, et al. Use of lung allografts from donation after cardiac death donors: a single-center experience[J]. Ann Thorac Surg, 2018, 105(1): 271-278. DOI: 10.1016/j.athoracsur.2017.07.023. [18] THUONG M, RUIZ A, EVRARD P, et al. New classification of donation after circulatory death donors definitions and terminology[J]. Transpl Int, 2016, 29(7): 749-759. DOI: 10.1111/tri.12776. [19] BOFFINI M, RICCI D, BONATO R, et al. Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion[J]. Eur J Cardiothorac Surg, 2014, 46(5): 789-793. DOI: 10.1093/ejcts/ezu239. [20] LIU F, LU Y, WEI D, et al. Effect of ex vivo lung perfusion on storage of isolated lungs[J]. Ann Palliat Med, 2020, 9(2): 359-367. DOI: 10.21037/apm.2020.03.08. [21] WONG A, ZAMEL R, YEUNG J, et al. Potential therapeutic targets for lung repair during human ex vivo lung perfusion[J]. Eur Respir J, 2020, 55(4): 1902222. DOI: 10.1183/13993003.02222-2019. [22] TANE S, NODA K, TOYODA Y, et al. Bronchial-arterial-circulation-sparing lung preservation: a new organ protection approach for lung transplantation[J]. Transplantation, 2020, 104(3): 490-499. DOI: 10.1097/TP.0000000000002984. [23] OTO T, GRIFFITHS AP, ROSENFELDT F, et al. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation[J]. Ann Thorac Surg, 2006, 82(5): 1842-1848. DOI: 10.1016/j.athoracsur.2006.05.088. [24] AL-NAAMANI N, PAN HM, ANDERSON MR, et al. Thoracic visceral adipose tissue area and pulmonary hypertension in lung transplant candidates. the lung transplant body composition study[J]. Ann Am Thorac Soc, 2020, 17(11): 1393-1400. DOI: 10.1513/AnnalsATS.202003-247OC. [25] ANDERSON MR, UDUPA JK, EDWIN E, et al. Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study[J]. J Heart Lung Transplant, 2019, 38(12): 1246-1256. DOI: 10.1016/j.healun.2019.08.013. [26] LEE JC, CHRISTIE JD. Primary graft dysfunction[J]. Clin Chest Med, 2011, 32(2): 279-293. DOI: 10.1016/j.ccm.2011.02.007. [27] HU CX, CHEN WH, HE JX, et al. Lung transplantation in China between 2015 and 2018[J]. Chin Med J (Engl), 2019, 132(23): 2783-2789. DOI: 10.1097/CM9. 0000000000000543. [28] GEUBE MA, PEREZ-PROTTO SE, MCGRATH TL, et al. Increased intraoperative fluid administration is associated with severe primary graft dysfunction after lung transplantation[J]. Anesth Analg, 2016, 122(4): 1081-1088. DOI: 10.1213/ANE.0000000000001163. [29] WANG X, O'BRIEN ME, YU J, et al. Prolonged cold ischemia induces necroptotic cell death in ischemia-reperfusion injury and contributes to primary graft dysfunction after lung transplantation[J]. Am J Respir Cell Mol Biol, 2019, 61(2): 244-256. DOI: 10.1165/rcmb.2018-0207OC. [30] KIZILTUG H, FALTER F. Circulatory support during lung transplantation[J]. Curr Opin Anaesthesiol, 2020, 33(1): 37-42. DOI: 10.1097/ACO.0000000000000806. [31] MAGOULIOTIS DE, TASIOPOULOU VS, SVOKOS AA, et al. Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a Meta-analysis[J]. Gen Thorac Cardiovasc Surg, 2018, 66(1): 38-47. DOI: 10.1007/s11748-017-0836-3. [32] HAYANGA JWA, CHAN EG, MUSGROVE K, et al. Extracorporeal membrane oxygenation in the perioperative care of the lung transplant patient[J]. Semin Cardiothorac Vasc Anesth, 2020, 24(1): 45-53. DOI: 10.1177/1089253219896123. [33] HOETZENECKER K, BENAZZO A, STORK T, et al. Bilateral lung transplantation on intraoperative extracorporeal membrane oxygenator: an observational study[J]. J Thorac Cardiovasc Surg, 2020, 160(1): 320-327. DOI: 10.1016/j.jtcvs.2019.10.155. [34] FRICK AE, ORLITOVÁ M, VANSTAPEL A, et al. A novel experimental porcine model to assess the impact of differential pulmonary blood flow on ischemia-reperfusion injury after unilateral lung transplantation[J]. Intensive Care Med Exp, 2021, 9(1): 4. DOI: 10.1186/s40635-021-00371-1. [35] SUNDER T. Extracorporeal membrane oxygenation and lung transplantation[J]. Indian J Thorac Cardiovasc Surg, 2021, 19: 1-11. DOI: 10.1007/s12055-020-01099-5. [36] MITZMAN B. Commentary: taking matters into your own hands: venoarterial extracorporeal membrane oxygenation for controlled reperfusion during lung transplantation[J]. J Thorac Cardiovasc Surg, 2020, 160(1): 330-331. DOI: 10.1016/j.jtcvs.2019.11.037. [37] PENA JJ, BOTTIGER BA, MILTIADES AN. Perioperative management of bleeding and transfusion for lung transplantation[J]. Semin Cardiothorac Vasc Anesth, 2020, 24(1): 74-83. DOI: 10.1177/1089253219869030. [38] SEAY T, GUINN N, MAISONAVE Y, et al. The association of increased FFP: RBC transfusion ratio to primary graft dysfunction in bleeding lung transplantation patients[J]. J Cardiothorac Vasc Anesth, 2020, 34(11): 3024-3032. DOI: 10.1053/j.jvca.2020.05.043. [39] SYRETT AJ, HUANG A. Transfusion and primary graft dysfunction after lung transplantation: all about the ratio?[J]. J Cardiothorac Vasc Anesth, 2020, 34(11): 3033-3035. DOI: 10.1053/j.jvca.2020.07.012. [40] 胡春晓, 王志萍, 许波, 等. 肺移植术中肺动脉高压的麻醉管理[J]. 中华器官移植杂志, 2019, 40(3): 189-192. DOI: 10.3760/cma.j.issn.0254-1785.2019.03.017.HU CX, WANG ZP, XU B, et al. Anesthesia management of pulmonary hypertension during lung transplantation[J]. Chin J Organ Transplant, 2019, 40(3): 189-192. DOI: 10.3760/cma.j.issn.0254-1785.2019.03.017. [41] KACHULIS B, MITREV L, JORDAN D. Intraoperative anesthetic management of lung transplantation patients[J]. Best Pract Res Clin Anaesthesiol, 2017, 31(2): 261-272. DOI: 10.1016/j.bpa.2017.04.004. [42] 中华医学会麻醉学分会"肺移植术麻醉管理专家共识"工作小组. 肺移植术麻醉管理专家共识[J]. 中华麻醉学杂志, 2020, 40(7): 771-778. DOI: 10.3760/cma.j.cn131073.20200508.00702.Task Force on Anaesthesia Management for Lung Transplantation of Branch of Anesthesiology of Chinese Medical Association. Expert consensus on anaesthesia management for lung transplantation[J]. Chin J Anesthesiol, 2020, 40(7): 771-778. DOI: 10.3760/cma.j.cn131073.20200508.00702. [43] YAMADA Y, LAUBE I, JANG JH, et al. Sevoflurane preconditioning protects from posttransplant injury in mouse lung transplantation[J]. J Surg Res, 2017, 214: 270-277. DOI: 10.1016/j.jss.2017.03.021. [44] MARTIN AK, YALAMURI SM, WILKEY BJ, et al. The impact of anesthetic management on perioperative outcomes in lung transplantation[J]. J Cardiothorac Vasc Anesth, 2020, 34(6): 1669-1680. DOI: 10.1053/j.jvca.2019.08.037. -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 464
- HTML全文浏览量: 238
- PDF下载量: 76
- 被引次数: 0
